Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X.

Author:

Wong P C1,Price W A1,Chiu A T1,Duncia J V1,Carini D J1,Wexler R R1,Johnson A L1,Timmermans P B1

Affiliation:

1. Medical Products Department, E.I. du Pont de Nemours & Company, Wilmington, DE 19880-0400.

Abstract

In conscious 18-21-week-old spontaneously hypertensive rats, DuP 753, a nonpeptide angiotensin II receptor antagonist, given orally at 3 and 10 mg/kg or intravenously at 3, 10, and 30 mg/kg, reduced blood pressure dose dependently. It did not alter heart rate at these doses. At 10 mg/kg i.v., DuP 753 decreased blood pressure significantly for at least 24 hours, suggesting a long duration of the antihypertensive effect. Unlike saralasin, DuP 753 did not cause a transient increase in blood pressure. The acute antihypertensive efficacy of DuP 753 was greater than that of captopril. Our data indicate that, for captopril to reduce blood pressure to a similar extent as that of DuP 753, it would need to be supplemented by a diuretic. DuP 753 did not have an acute diuretic effect. Bilateral nephrectomy, but not inhibition of prostaglandin synthesis, abolished the antihypertensive effect of DuP 753, suggesting that the antihypertensive effect of DuP 753 is dependent on an active renin-angiotensin system. Furthermore, DuP 753 inhibited the pressor response to angiotensin II but not the responses to norepinephrine, vasopressin, and Bay K 8644 (a calcium agonist). As neither DuP 753 nor captopril decreased blood pressure acutely in Wistar-Kyoto normotensive rats, our results suggest that the renin-angiotensin system plays a significant role in the control of blood pressure in spontaneously hypertensive rats.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Internal Medicine

Reference34 articles.

1. Furukawa Y Kishimoto S Nishikawa K: Hypotensive imidazole derivatives. US Patent 4 340 598 issued to Takeda Chemical Industries Ltd Osaka Japan 1982

2. Furukawa Y Kishimoto S Nishikawa K: Hypotensive imidazole-5-acetic acid derivatives. US Patent 4 355 040 issued to Takeda Chemical Industries Ltd Osaka Japan 1982

3. Nonpeptide angiotensin II receptor antagonists: I. Pharmacological characterization of 2-n-buty1-4-chloro-l-(2-chlorobenzyl)imidazole-5- acetic acid, sodium salt (S-8307);Wong PC;J Pharmacol Exp Ther,1988

4. Non-peptide angiotensin II receptor antagonists. II . Pharmacology of S-8308

5. Carini DJ Wong PC Duncia JV: Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSAIDS. European Patent Application 0324377 issued to E. I. du Pont de Nemours & Co Inc Wilmington Delaware 1989

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3